Posted inDiabetes & Endocrinology news Pediatrics
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring
This study demonstrates that initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in children and adolescents with cystic fibrosis improves continuous glucose monitoring (CGM) metrics, correlating with better clinical outcomes.
